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Summary Among gastric cancer patients, the Rhesus D-negative phenotype correlated with increased tumour recurrence [all patients, n=
83, P= 0.026; curatively (RO) resected patients, n = 51, P= 0.093] and reduced overall survival time (all patients, log-rank P= 0.0028; RO
patients, log-rank P= 0.0003) and was identified in multivariate analysis as the most important independent prognostic marker in the R0
patient group (relative risk 9.1, P= 0.0013).
Keywords: gastric cancer; Rhesus factor; progression; prognosis; multivariate analysis
Identification of high-risk cancer patients and the development of
prognosis-oriented, multimodal therapy adapted to the individual
patient is one of the main goals of current oncological research.
Towards this end, much effort is currently being directed towards
the identification ofnew, independent prognostic parameters often
employing laborious molecular biological and immunohistolog-
ical approaches. In gastric cancer, a variety of cell adhesion mol-
ecules, secreted products and gene-regulatory proteins have been
identified as potential risk factors (Tahara, 1995). Among the
factors that are readily determined in tumour patients receiving
surgical treatment are the blood group antigens. In contrast to
extensive studies on the ABO system, the prognostic relevance of
the Rhesus factor has only been sporadically investigated
(Halvorsen, 1986; Cerny et al, 1987; Kvist et al, 1990, 1992;
Bryne et al, 1991a, b; Raitanen and Tammela, 1993) and has not
been reported for gastric cancer. The aim ofthe present study was
to evaluate the prognostic impact of the Rhesus phenotype in
gastric carcinoma patients.
PATIENTS AND METHODS
For a series of83 gastric cancerpatients undergoing surgical resec-
tion according to standard protocols, a panel of potential prog-
nostic parameters was evaluated. Patient-related factors included
sex and age. The ABO blood group antigens and the Rhesus D
antigen phenotype were serologically determined using standard
protocols. Treatment-associated variables considered extent of
operation and the presence of residual tumour after surgical treat-
ment. A curative resection (RO, n = 51) is one in which all macro-
scopically visible tumour has been removed (as determined by the
surgeon), and the surgical margins are microscopically tumour
free (as determined by the pathologist). Resections with residual
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microscopic or macroscopic tumour were defined as R1 (n = 10) or
R2 (n = 22) respectively. Tumour-associated factors included
depth of tumour invasion (pT), involvement oflymph nodes (pN),
distant metastasis at time of diagnosis (M) and tumour stage
(UICC-stage), classified according to the UICC (International
Union against Cancer) recommendations (1992). Tumour localiza-
tion and tumour diameter were determined and gross appearance of
the tumour was evaluated according to the Borrmann classifica-
tion. Histological tumour type was determined according to the
Lauren classification and the degree of tumour cell differentiation
(grading) was also assessed (Roder et al, 1993). Lymphatic and
blood vessel invasion and the presence of tumour cells in bone
marrow, which are proposed as new prognostic factors (Maehara et
al, 1995; Jauch et al, 1996), were also considered. Data for these
three parameters were not available for all patients.
Prospective follow-up was routinely performed every 6 months
and considered tumour recurrence and overall survival. In RO
patients, local and distant tumour relapse were evaluated, while in
R1 patients distant metastases only were considered. In patients
with macroscopic residual tumour (R2) tumourrecurrence was not
evaluated. Overall survival data were available for all patients.
Statistical analyses were performed using the Fisher's exact
probability test (two-tailed) to examine the association between
the Rhesus D phenotype and various clinicopathological and
immunohistological parameters. Univariate survival analysis was
performed using the Kaplan-Meier method (log-rank test).
Multivariate survival analysis was carried out using the Cox
proportional hazards regression model (SAS software program,
SAS Institute, Cary, NC, USA).
RESULTS AND DISCUSSION
The Rhesus D-negative phenotype was identified in 18.1% of the
total gastric cancer collective. The frequency of the Rhesus D-
negative phenotype in the investigated patient cohort is similar to
that found in the Caucasian population (Race and Sanger, 1975),
suggesting that the Rhesus D-negative phenotype does not predis-
pose to gastric cancer development.
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Table 1 Rhesus factor correlated with clinicopathological factors
nr Parameter Rhesus factor pD
Negative Positive
83 Sex
Male
Female
83 Age (median)
<67 years
> 67 years
83 ABO blood groupc
0
A
B
AB
83 Residual tumour
RO
R1/R2
83 Operationd
Not extended
Extended
83 pT classification
T1/T2
T3/T4
83 pN classification
NO
N1/N2
83 M classification
MO
Ml
83 UICC stage
1/11/111A
IIIB/IV
83 Tumour localization
Cardia
Other sites
83 Tumour diameter
<50 mm
> 50 mm
83 Gross appearance
Borrmann
B1/B2
B3/B4
83 Tissue architecture
Lauren
Intestinal
Diffuse/mixed
83 Cellular differentiation
Grading
G1/G2
G3/G4
73 Lymphatic vessel invasion*
Absent
Present
70 Blood vessel invasion*
Absent
Present
63 Bone marrow statuse,e
Negative
Positive
6
9
10
5
6
7
2
0
39
29
35
33
25
31
10
2
6
9
11
4
45
23
51
17
7
8
2
13
36
32
13
55
8
7
6
9
44
24
32
36
3
12
18
50
25
43
3
12
6
9
39
29
5
10
36
32
2
13
0.26
._
0.39 a.
0.76
0.039#
0.75
1.00
0.75
0.50
0.25
0.00
1.00
0.78
0.46
0.39 D
co .0 0
cL
0.58
0.75
0.75
0.50
0.25
0.25
0.00
Rh+
0.0 25.0 50.0 75.0
Months
B
100
Rh+
Rh-
0.0 25.0 50.0 75.0 100
0.26 Months
Figure Kaplan-Meier survival curves of gastric cancer patients according to
the Rhesus D phenotype. (A) total patients; Rhesus D-positive (Rh+) patients
(n = 68) compared with Rhesus D-negative (Rh-) patients (n = 15), log-rank
0.25 P= 0.0028. (B) RO patients; Rhesus D-positive patients (n = 45) compared
with Rhesus D-negative patients (n = 6), log-rank P= 0.0003
n 13 22
46
10
50 12
4
9
18
39
7
4
22
30
an, number of investigated patients. bp, significance according to the
exact Fisher's probability test (two-tailed). cBlood group A vs blood group 0
was considered. dAn extended operation was performed when tumour
was infiltrated in neighbouring organs. ePatients with a second carcinoma
were excluded. *Data were not available for all patients. #Significance level
P< 0.05.
Examination ofthe relationship between Rhesus factor distribu-
tion and a variety ofclinicopathological factors revealed a signifi-
cant correlation only with the presence of residual tumour after
surgery (Table 1). The Rhesus D-negative phenotype was detected
in only 11.8% (6 out of51) ofthe RO patients, but in 28.1% (9 out
of 32) of the patients with macroscopic (R2) or microscopic (RI)
residual tumour (P = 0.039). This would appear to reflect an asso-
ciation between the Rhesus D-negative phenotype and advanced
disease at time of diagnosis. This relationship was further
supported by the fact that all survivors among the RO patients (n =
17) were Rhesus positive. No significant correlation between
Rhesus phenotype and any other clinicopathological factor was
observed, neither in the total patient group (Table 1) nor in the RO
patients (data not shown) confirming the results obtained for other
tumour types (Kvist et al, 1990; Raitanen and Tammela, 1993;
Slater et al, 1993). No correlation was found between the Rhesus
phenotype and the expression of the cell adhesion molecules
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Table 2 Clinicopathological factors univariately and multivariately influencing
survival of the total patient group and the RO patient group
Parameter" Univariate Multivariate
Pb prp Relative 95%
risk intervald
Totalpatient group
Age 0.033 NS - -
Rhesus factor 0.0028 NS -
Residual tumoure 0.0001 0.0001 3.4 1.8-6.4
Operation 0.0001 NS -
pT classificatione 0.0017 0.0001 3.3 1.8-5.8
pN classificatione 0.0003 0.032 2.0 1.1-3.6
M classificatione 0.0001 0.012 2.3 1.2-4.4
UICC stage' 0.0001 NI - -
Tumour diameter 0.035 NS - -
Gross appearance 0.015 NS - -
Lymphatic vessel invasion' 0.012 NI - -
Blood vessel invasion' 0.0004 NI - -
ROpatientgroup
Rhesus factore 0.0003 0.0013 9.1 2.4-34.9
Operatione 0.0001 0.0008 6.6 2.2-19.8
pN classificatione 0.012 0.0024 4.9 1.8-13.6
M classification 0.0034 NS -
UICC stage' 0.002 NI
Tumour diameter 0.033 NS
aParameter definitions are given in Table 1. bP-value was evaluated using the
log-rank test. cP-value was evaluated using the chi-square test. d95%
interval, 95% confidence interval. eMultivariate risk factor (unfavourable vs
favourable feature); residual tumour (R1/2 vs RO), pT (T3/4 vs T1/2), pN
(N1/2 vs NO), M (Ml vs MO), Rhesus factor (Rh- vs Rh+), operation (extended
vs not extended, 'UICC stage, which is reflected by the TNM classification
and variables regarding vessel invasion which have missing data were not
included in the multivariate analysis. NS, not significant; NI, not included.
E-cadherin and CD44, the immunologically relevant HLA ABC
and HLA DR antigens, the accessory molecules ICAM-1 and
LFA-3 and the components of the uPA protease system by the
primary tumour (data not shown).
Analysis oftumour recurrence and overall survival revealed that
the Rhesus D-negative phenotype was associated with poor
outcome in both patient cohorts. In the total patient group, local or
distant tumour relapse was evaluable in 56 patients (RO, 50 out of
51; R1, 6 out of 10). Tumour recurrence was more frequent in
Rhesus D-negative patients (8 out of9) than in Rhesus D-positive
patients (21 out of 47; P = 0.026; median follow-up 12 months,
range 1-82 months). A similar trend was observed in the RO
group. Tumour recurrence was demonstrable in five out of six
Rhesus D-negative patients, but only in 43% (19 out of44) of the
Rhesus D-positive patients (P = 0.093, median follow-up 24
months, range 1-82 months). Kaplan-Meier survival curves show
that Rhesus D-negative patients had significantly shorter overall
survival times than Rhesus D-positive patients in both the total
(n = 83) and in the RO (n = 51) cohort (Figure).
Multivariate analysis was performed to determine if the Rhesus
D-negative phenotype is an independent predictor of poor prog-
nosis. This analysis included all parameters listed in Table 1
univariately influencing survival ofthe patient cohorts at a signifi-
cance level of P < 0.05 (Table 2). In the total patient collective,
conventional clinicopathological parameters, i.e. residual tumour
after surgical treatment, advanced depth of tumour invasion and
the presence of lymph node and distant metastases at time of
diagnosis, were found to be independent determinants of poor
prognosis (Table 2). The Rhesus factor was not an independent
prognostic factor in the total patient cohort. In contrast, in the
group of RO patients who are characterized by a more favourable
tumour stage, the Rhesus D-negative phenotype was found to be a
powerful independent predictor of poor prognosis (P=0.0013;
relative risk 9.1), ranking before the positive nodal status and the
performance of an extended operation (Table 2).
An association between Rhesus D-negative phenotype and
tumour prognosis has also been observed in other tumours. In oral
squamous cell carcinoma, Rhesus D-negative phenotype was iden-
tified as an independent parameter associated with tumour
progression (Bryne et al, 199la, b). In contrast, in colorectal carci-
noma Rhesus D-negative phenotype was associated with a
favourable tumour stage (Halvorsen, 1986) and in urogenital carci-
nomas the Rhesus phenotype had no prognostic impact (Kvist et
al, 1990, 1992; Raitanen and Tammela, 1993). Interestingly, in
small-cell lung cancer, no association was observed between
Rhesus phenotype and survival but an increased frequency of
Rhesus D-negative individuals was seen, suggesting a predisposal
towards this tumour (Cerny et al, 1987,-1992).
The role of the Rhesus factor in tumour progression remains
unclear. The function of Rhesus D itself, a molecule that has the
structural characteristics ofan ion transporter (Telen, 1995), may be
important in the maintenance ofnormal cell growth and differentia-
tion. An alternative possibility is thatthe Rhesus D-negative pheno-
type is associated with the loss or alteration in one or more genes
directly involved in tumour development. The Rhesus D gene is
located on chromosome 1 between p34 and p36 (Cherif-Zahar,
1991), a region recently shown to be the location of a putative
gastric carcinoma tumour-suppressor gene (Sano et al, 1991; Ezaki
et al, 1996). Inasmuch as the Rhesus D-negative phenotype is
usually associated with a deletion ofthis gene (Hyland et al, 1994),
it is possible that this tumour-suppressor gene is also altered or
deleted in some Rhesus D-negative individuals, a situation which
could directly influence tumour growth and/or tumour progression.
Approximately 50% of curatively (RO) resected gastric cancer
patients will die oftumour recurrence despite a favourable tumour
stage. In the present study, the Rhesus D-negative phenotype has
been detected as a new independent factor ofpoor prognosis in RO
resected gastric cancer patients. This finding suggests that the
routinely evaluated Rhesus phenotype may be an important marker
for the selection of RO resected, high-risk cancer patients who
should be considered in prognosis-associated multimodal therapy.
ACKNOWLEDGEMENTS
The authors thank Mrs C Lorenz and Mr H Spatz for technical
assistance, Dr R Babic and Dr MM Heiss for providing the data of
the uPA protease system and Dr C Cramer forhelp in the organiza-
tion of the follow-up data. This study was supported by the Curt-
Bohnewand-Fonds.
REFERENCES
Bryne M, Eide GE, Lilleng R, Langmark F, Thrane PS and Dabelsteen E (1991a) A
multivariate study ofthe prognosis oforal squamous cell carcinomas. Cancer
68: 1994-1998
Bryne M, Thrane PS, Lilleng R and Dabelsteen E (199lb) Prognostic value
of Rhesus blood groups in oral squamous cell carcinomas. Cancer 68:
2213-2216
Cancer Research Campaign 1997 British Joural of Cancer (1997) 75(9), 1291-12941294 B Mayer etal
Cerny T, Blair V, Anderson H. Bramwell V and Thatcher N (1987) Pretreatment
prognostic factors and scoring system in 407 small-cell lung cancer patients.
Int J Cancer 36: 146-149
Cerny T. Fey MF, Oppliger R, Castiglione M, Nachbur B, Gertsch M, Gasser A, Joss
RA, Thatcher N, Lind M, Von Rohr A and Nydegger UE (1992) Prevalence of
the Rhesus-negative phenotype in Caucasian patients with small-cell lung
cancer (SCLC). Int J Canicer 54: 504-506
Cherif-Zahar B (1991) Localization ofthe human Rh blood group gene structure to
chromosome region Ip34.3-1p36 by in situ hybridization. Huni Genet 86:
398-400
Ezaki T, Yanagisawa A, Ohta K, Aiso S, Watanabe M, Hibi T, Kato Y,
Nakajima T. Ariyama T, Inazawa J, Nakamura Y and Horii A (1996) Deletion
mapping on chromosome Ip in well-differentiated gastric cancer. Br J Cancer
73: 424-428
Halvorsen TB (I1986) ABO blood groups, Rhesus types, and colorectal
adenocarcinoma. A retrospective study of 747 cases. Scand J Gastroenterol 21:
979-983
Hyland CA, Wolter LC and Saul A (1994) Three unrelated Rh D gene
polymorphisms identified among blood donors with Rhesus CCee (r'r')
phenotypes. Blood 84: 321-324
Jauch KW, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, Eissner H-J,
Riethmuller G and Schildberg FW (1996) The prognostic significance of bone
marrow micrometastases in patients with gastric cancer. J Clin Oncol 14:
1810-1817
Kvist E, Krogh J and Rye B (1990) Blood groups and urothelial tumours of the
upper urinary tract. ScandI Urol Nephrol 24: 253-255
Kvist E, Krogh J and Hjortberg P (1992) Prognostic variables in patients with
prostate cancer: influence ofblood group ABO (H), the Rhesus system, age,
differentiation, tumour stage and metastases. Int Urol Nephrol 24: 417-423
Maehara Y, Oshiro T, Baba H, Ohno S, Kohnoe S and Sugimachi K (1995)
Lymphatic invasion and potential for tumour growth and metastasis in patients
with gastric cancer. Surgeryl 117: 380-385
Race RR and Sanger R (1975) Blood Groups in Mon, 6th edn. Oxford: Blackwell
Scientific Publications
Raitanen MP and Tammela TLJ (I1993) Relationship between blood groups and
tumor grade, number, size, stage, recurrence and survival in patients with
transitional cell carcinoma of the bladder. ScandJ Urol Nephrol 27: 343-347
Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ and the German
Gastric Carcinoma Study Group ( 1993) Prognostic factors in gastric
carcinoma. Results of the German Carcinoma Study 1992. Cancer 72:
2089-2097
Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H, Nakamura Y,
Kajiyama G and Tahara E (1991) Frequent loss of heterozygosity on
chromosomes lq, Sq, and 17p in human gastric carcinomas. Cancer Res 51:
2926-2931
Slater G, Itzkowitz S, Azar S and Aufses JR AH (1993) Clinicopathologic
correlations of ABO and Rhesus blood type in colorectal cancer. Dis Co/lot
Rectum 36: 5-7
Tahara E (1995) Genetic alterations in human gastrointestinal cancers. Cancer 75:
1410-1417
Telen MJ ( 1995) Erythrocyte blood group antigens: not so simple after all. Blood 85:
299-306
British Journal ofCancer (1997) 75(9), 1291-1294 © Cancer Research Campaign 1997